The Titration Trap: How introductory pricing costs you more in the long run
This article discusses medicines which are legally classified as Prescription-Only Medicine (POM). It is not possible to obtain a POM through Aster without a consultation with a prescribing clinician which results in a prescription, as per UK law and guidance.
With the cost of living placing continuous pressure on household budgets, managing personal finances has become as much of a priority as managing health. When making the decision to invest in life-changing medical treatments like Mounjaro or Wegovy, it is entirely logical that patients hunt for the best value.
But a predatory financial trend is sweeping through high-volume, transactional digital clinics: we call it the Introductory Pricing Trap.
You have likely seen the ads plastered across social media—flashing banners promising powerful weight loss injections for a strikingly low starting price. You may have even enquired with one of these clinics and been bombarded with texts and emails prompting you to ‘buy’. (See our article on marketing within the online weight management industry).
What these companies bury in the fine print is a commercial bait-and-switch model designed to lock you into a costly subscription before hitting you with steep, mandatory price increases as your dosage escalates. You may or may not be financially penalised for exiting a subscription prematurely, but regardless, suddenly stopping a medicine after at least 4 weeks’ treatment with no downward titration is not recommended by our clinicians.
At Aster, we believe that any clinical care requires absolute financial transparency. A patient should never have to compromise their biological titration schedule because of hidden retail markups.
The Anatomy of a Medical Bait-and-Switch
GLP-1 and GIP medications are inherently designed around a clinical process called titration, which is gradually increasing your dose as frequently as every four weeks (e.g., shifting Mounjaro from 2.5mg up to 5mg, 7.5mg, and eventually higher maintenance doses) to allow your digestive system to adapt safely.
The British National Formulary (BNF) lays down these exact timelines for weight management drugs in line with the way the medicines were initially clinically-trialled and licensed.. This framework serves as clinical proof that titration is a biological necessity for gastrointestinal adaptation. So, any provider that lets you begin by ‘choosing a dose’ above the lowest strength, to check-out, where you haven’t previously been using the medicine, is going against current national guidance for safe use of the medicine.
Transactional subscription clinics exploit this biological timeline as a commercial sales funnel:
The Loss-Leader Hook: You are lured in with a heavily discounted introductory price for Month 1 (the 2.5mg starter dose).
The Auto-Enrollment Lock: You are required to sign up for a mandatory monthly subscription to secure that initial discount.
The Escalation Penalty: Once you are clinically committed and your body has adjusted, the clinic dramatically hikes the price for Month 2 and beyond as you move up in strength.
According to guidelines from National Institute for Health and Care Excellence (NICE), patients need a steady, financially predictable runway to maintain their dosages without abrupt interruptions for these treatments to work safely and effectively. When sudden price hikes hit unannounced, it can trigger severe safety gaps if patients are priced out of titration steps, forcing irregular dosing or an abrupt halt to care.
Hidden Fees: The Retail ‘Drip Pricing’ Tactics
Worse still, the headline price you see on e-commerce pharmacy apps frequently omits the structural necessities of safe clinical care.
High-volume providers commonly engage in what consumer watchdogs call drip pricing - disguising the true cost of a service by hitting consumers with unexpected fees later in the purchasing journey.
Patients using subscription-heavy platforms may find that their ‘cheap’ monthly rate doesn't actually include essential components, leaving them hit with hidden, separate bills for mandatory clinical consultation fees, cold-chain delivery charges, or necessary medical consumables like sharps disposal bins and needles.
The Chartered Trading Standards Institute (CTSI) heavily regulates these practices across UK digital storefronts, detailing the illegality of subscription traps where terms regarding future price increases are intentionally buried or made unnecessarily complex to opt-out of. They mandate that any escalating cost over time must be displayed transparently in upfront pounds and pence.
Furthermore, academic legal frameworks found in Pharmacy Law and Practice highlight that separating the cost of clinical assessments from the physical medicine to falsely lower headline prices violates the spirit of the law, which views online consultation and supply as one unified healthcare service.
What UK Regulators and Professional Bodies Say
This lack of transparency hasn’t just frustrated patients; it has triggered aggressive intervention from national regulatory bodies who argue that prescription-only medicines (POMs) should never be treated like exploitative gym memberships.
Competition & Markets Authority (CMA): The CMA explicitly outlaws drip pricing and artificially lowering initial headline prices while obscuring recurring commitments or hiding steep titration hikes in the small print.
The General Pharmaceutical Council (GPhC): In its statutory guidance for remote pharmacy services, the GPhC establishes that digital environments must be transparent and explicitly guard against commercial arrangements that distort patient care or compromise a patient's ability to safely continue an established treatment plan.
Medicines and Healthcare Products Regulatory Agency (MHRA): The MHRA mandates that a POM is a strictly non-promotional medical treatment and cannot legally be treated like a high-volume retail product.
The Advertising Standards Authority (ASA): Working alongside joint directives, the ASA strictly prohibits online platforms from using consumer-facing public price marketing and financial incentives to nudge vulnerable patients into high-risk medical treatments.
The Aster Ethos: Radical, Predictable Pricing
Professional standards set by the Royal Pharmaceutical Society (RPS) assert that part of appropriate, ethical prescribing means ensuring a treatment plan is sustainably viable for the patient from day one. Starting a medication via an artificial loss-leader price, only for a patient to stop abruptly when maintenance costs spike, violates the basic ethical codes of the pharmacy profession.
Reports from the Health Services Safety Investigation Body (HSSIB) have also highlighted how fragmented, uncoordinated online prescribing leaves patients vulnerable when financial models trigger high patient dropout rates due to sudden affordability issues.
At Aster, we fundamentally refuse to participate in retail gimmicks. Weight management is a medical journey, and you deserve a predictable financial runway so you can plan your care with complete peace of mind.
We do not use loss-leaders, we do not deploy predatory auto-renewing subscription contracts, and we will never surprise you with unannounced pricing surges.
Our pricing is flat, honest, and completely transparent across our treatment options. Your automated clinical reviews, shipping, needles, and sharps disposal bins are entirely included in the price you see, which covers the dispensing cost of your medicine.
Reclaiming your metabolic health requires a consistent partnership based on trust, safety, and transparency. Don't fall victim to corporate subscription traps that view your healthcare as a recurring monthly invoice. Choose Aster, where your clinical safety, and financial clarity, always comes first.
Sources
Royal Pharmaceutical Society (RPS) Competency Framework for All Prescribers & Professional Standards for Digital Pharmacy Services.
https://www.rcpharm.org/professional-standards/a-competency-framework-for-all-prescribers/
Health Services Safety Investigation Body (HSSIB) National Investigation Report: Patient Safety Risks in Independent Online Prescribing.
https://www.hssib.org.uk/patient-safety-investigations/online-prescribing-challenges-and-opportunities-to-improve-patient-safety/investigation-report/
National Institute for Health and Care Excellence (NICE) NICE Technology Appraisal Guidance [TA1026]: Tirzepatide for managing overweight and obesity (Section 1.2).
https://www.nice.org.uk/guidance/ta1026/chapter/1-Recommendations
British National Formulary (BNF) Prescribing and Titration Protocol Frameworks for Incretin Mimetics.
https://cks.nice.org.uk/topics/diabetes-type-2/prescribing-information/glp-1-receptor-agonists/
Chartered Trading Standards Institute (CTSI) CTSI Guidance for Traders on Pricing Practices
https://www.businesscompanion.info/en/guidance-for-traders-on-pricing-practices
The General Pharmaceutical Council (GPhC) Guidance for Registered Pharmacies Providing Pharmacy Services at a Distance, Including on the Internet.
https://assets.pharmacyregulation.org/files/2025-02/gphc-guidance-registered-pharmacies-providing-pharmacy-services-distance-february-2025.pdf
Competition & Markets Authority (CMA) Consumer Protection Enforcement Priorities under the Digital Markets, Competition and Consumers Act (DMCCA) & Pricing Transparency Guidance (CMA209).
https://assets.publishing.service.gov.uk/media/6a3a92e333bc5beefd3c47b0/CMA209_Unfair_commercial_practices__price_transparency_13.2.26__2_.pdf
Medicines and Healthcare Products Regulatory Agency (MHRA) The Blue Guide: Advertising and Promotion of Medicines in the UK
https://assets.publishing.service.gov.uk/media/6012d7f2d3bf7f05b92f6cfc/BG_2020_Brexit_Final_version.pdf
The Advertising Standards Authority (ASA) & CAP Enforcement Notice: Advertising of Prescription-Only Weight-Loss Treatments (Joint MHRA/GPhC Directive) & CAP Code Rule 12.12.
https://assets.pharmacyregulation.org/files/2025-09/Enforcement-Notice-prescription-only-medicines-used-for-weight-management-September-2025.pdf?VersionId=nUC_VEq4b2qZE3G2I1dibaU3jMM6nHp_
This article was written by
Sally Proudman
Operations manager
